| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_616b071a8f2decfc2ed30a71524e6f76 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G65-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72dabad8749487970afbef844c5914cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4ceffe0810a51611bedc87451ccb1a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35fe24838fc4d8dad20d6bb4b7ed59ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c012852128641f091290c7894e9e947
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e7aa7681833ff76f39fef7002f1b678
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de59b09423ab7d755e9c6d1af26b29fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffee0f5c0eed064aeacf6383220cf5d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d2ded8f4317077f3fd1093e71b2b05d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9eee2002a76af02ea5f007a9ab2faa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9761d87323c7707f5adc64cef7302b31 |
| publicationDate |
2015-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-104650344-A |
| titleOfInvention |
Conjugate of PEG modified irinotecan |
| abstract |
The invention discloses a PEG modified irinotecan conjugate having a chemical formula as shown in a formula (1). The invention discloses a preparation method of the conjugate and such research on the conjugate as in-vitro release test and MTT test. The preparation method of the PEG modified irinotecan conjugate comprises the following steps: carboxylating terminal carboxyls of PEG (polyethylene glycol) by using butanedioic anhydride; activating with an active ester (NHS); and connecting the processed PEG with irinotecan by using amino acid serving as a connecting arm, thus obtaining PEG modified irinotecan. The PEG modified irinotecan has the advantages that the water solubility of drugs is enhanced, toxic and side effects of drugs are reduced and an in-vitro slow release effect is achieved. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113925973-A |
| priorityDate |
2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |